Phase 1 results of safety and tolerability in a rush oral immunotherapy protocol to multiple foods using Omalizumab
نویسندگان
چکیده
منابع مشابه
Phase 1 results of safety and tolerability in a rush oral immunotherapy protocol to multiple foods using Omalizumab
BACKGROUND Up to 30% of patients with food allergies have clinical reactivity to more than one food allergen. Although there is currently no cure, oral immunotherapy (OIT) is under investigation. Pilot data have shown that omalizumab may hasten the ability to tolerate over 4 g of food allergen protein. OBJECTIVE To evaluate the safety and dose tolerability of a Phase 1 Single Site OIT protoco...
متن کاملSuccessful desensitization in a boy with severe cow’s milk allergy by a combination therapy using omalizumab and rush oral immunotherapy
BACKGROUND Rush oral immunotherapy (OIT) combined with omalizumab (OMB) has been reported to be an effective and safe treatment for severe milk allergies. However, no report has described long-term follow-up observations after OMB discontinuation. The purpose of this case report was to evaluate the safety and efficacy of rush OIT in combination with OMB during a long period of treatment. CASE...
متن کاملepidemiological study of oral and pharyngeal cancers in kermanshah province from march 1993 to march 2006
چکیده ندارد.
15 صفحه اولSafety and efficacy of an imported fire ant rush immunotherapy protocol with and without prophylactic treatment.
BACKGROUND Hypersensitivity to the sting of the imported fire ant (IFA) is a growing and significant cause of morbidity and mortality in the United States. Conventional immunotherapy with IFA whole body extract (WBE) has been shown to be effective; however, rush immunotherapy (RIT) with IFA WBE has not been studied. OBJECTIVE In this study, we evaluated the safety and efficacy of RIT with IFA...
متن کاملThe safety of multiple oral immunotherapy in phase one studies at a single center
Background There are over 15 million people with food allergies, 38% of which suffer from more than 1 food allergy. With increasing interest in oral immunotherapy (OIT) as a potential treatment, the safety of ingesting known allergens is a major concern. Little to no data are available for OIT with multiple simultaneous allergens. Also, the effect of omalizumab as adjunctive therapy in rush mul...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Allergy, Asthma & Clinical Immunology
سال: 2014
ISSN: 1710-1492
DOI: 10.1186/1710-1492-10-7